You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest Type 2 Issues Articles
Popular Type 2 Issues Articles
Highly Recommended Type 2 Issues Articles
Scientists hope that a new GLP-1 analog will last longer in the body, allowing for less frequent dosing and fewer side effects.
A new glucagon-like peptide-1 (GLP-1) analog for type 2s that might require dosing only once a month is now in pre-clinical (animal) studies. GLP-1, which increases insulin secretion from the pancreas, is a mighty helpful molecule, but with a sadly brief lifespan. It's broken down in the body within minutes by the enzyme DPP-4. That's why drugs like Merck's Januvia, a DPP-4 inhibitor, is effective: blocking DPP-4 subsequently increases the amount of GLP-1 in the system.
Another way to tackle the problem of GLP-1's vulnerability to DPP-4 is to make a GLP-1 analog: a molecule that works like GLP-1, but can hide from or resist DPP-4. Byetta (exenatide), for example, is a GLP-1 analog that has been tweaked enough to stay in the system for awhile, but it still needs to be injected twice a day before meals.
The new GLP-1 analog (VRS-859), created by Versartis, is a recombinant fusion protein. That is, it's made up of exenatide attached to XTEN. XTEN is a water-loving amino acid sequence that "covers" exenatide, hiding it from DPP-4 and protecting it from breakdown. This will, it is hoped, let the GLP-1 carry out its good works for a longer time, allowing for less frequent dosing and fewer side effects.
Sources:
Categories: Insulin, Medications Research, Research, Type 2 Issues
0 comments -
Aug 25, 2009
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.


Email to a Friend
Send a link to this page to your friends and colleagues.